Analytical Data
-
Gene name
SGCa
- Application
-
Alternative Names
SGCa；ADL；DAG2；Alpha-sarcoglycan
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q16586
-
Expression Region
1-387aa
-
AA Sequence
MAETLFWTPLLVVLLAGLGDTEAQQTTLHPLVGRVFVHTLDHETFLSLPE HVAVPPAVHITYHAHLQGHPDLPRWLRYTQRSPHHPGFLYGSATPEDRGL QVIEVTAYNRDSFDTTRQRLVLEIGDPEGPLLPYQAEFLVRSHDAEEVLP STPASRFLSALGGLWEPGELQLLNVTSALDRGGRVPLPIEGRKEGVYIKV GSASPFSTCLKMVASPDSHARCAQGQPPLLSCYDTLAPHFRVDWCNVTLV DKSVPEPADEVPTPGDGILEHDPFFCPPTEAPDRDFLVDALVTLLVPLLV ALLLTLLLAYVMCCRREGRLKRDLATSDIQMVHHCTIHGNTEELRQMAAS REVPRPLSTLPMFNVHTGERLPPRVDSAQVPLILDQH
-
Molecular Weight
69 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SGCa, or sarcoglycan alpha, is a crucial component of the dystrophin-glycoprotein complex found in skeletal and cardiac muscle cells, playing a vital role in maintaining cellular integrity and function. Mutations in the SGCA gene are associated with a group of muscular dystrophies, particularly limb-girdle muscular dystrophy type 2D (LGMD2D), which leads to progressive muscle weakness and degeneration. The study of SGCa recombinant proteins has gained significant attention as researchers strive to understand the molecular mechanisms involved in muscle cell stability and pathology. By producing and characterizing these recombinant proteins, scientists aim to elucidate the structure-function relationships of SGCa, explore potential therapeutic avenues, and assess their role in muscle regeneration and repair. Furthermore, the development of animal models expressing mutated forms of SGCa allows for in vivo studies, fostering insights into disease progression and potential interventions. As advancements in gene editing and protein engineering continue, the exploration of SGCa recombinant proteins presents opportunities for innovative treatments that could mitigate the effects of muscular dystrophies and improve the quality of life for affected individuals. Overall, the ongoing research on SGCa and its recombinant forms represents a promising frontier in understanding muscular dystrophies and developing targeted therapies.
